1. Progress of the NSCLC Revolution

2. Agenda

3. Molecular Testing in NSCLC: Where Are We Going?

4. The NGS Era in France

5. Current Molecular Testing Guidelines

6. Tumor Responses to Crizotinib in ROS1-Rearranged NSCLC

7. First-Line Dabrafenib-Trametinib in BRAF-Positive NSCLC: PFS

8. The Potential of Precision Medicine

9. Faculty Commentary NGS and Testing

10. Molecular Testing Workflow

11. Comparison of Testing Methods

12. Faculty Commentary: Testing and Treatments

13. Summary of Frontline Immunotherapy Trials

14. Lack of Correlation Between TMB and PD-L1

15. Treating New Molecular Targets in NSCLC: How Are We Progressing?

16. Smoking Status in Patients With Uncommon Mutations

17. Overview of Select cMET Inhibitors: MET Amplification as a Target

18. Overview of Select cMET Inhibitors: MET Exon 14 Mutations as a Target

19. Overview of Select ERBB2/HER2 Inhibitors: HER2 Exon 20 Mutations as a Target

20. Overview of Select ERBB2/HER2 Inhibitors: HER2 Amplification as a Target

21. Overview of Select RET Inhibitors

22. Other RET Inhibitors of Interest in Early Trials

23. Data on TRK Inhibitors

24. Resistance Mechanisms

25. Immunotherapy in NSCLC: Where Have We Got To?

26. Monotherapy With Immunotherapy

27. Combination Chemotherapy and Immunotherapy

28. Emerging Data From IMpower132

29. CheckMate 227 Trial Design

30. Nivolumab Combinations: CheckMate 227

31. Frontline Immunotherapy in EGFR-Positive Patients

32. Second-Line Immunotherapy in EGFR/ALK-Positive Patients

33. Abbreviations

34. Abbreviations (cont)

35. Abbreviations (cont)

36. Abbreviations (cont)